RESUMEN
Canine splenic hemangiosarcoma has a high metastatic rate and short survival time. Currently, the main prognostic parameters are tumor stage and therapy, while data on histologic parameters, such as grade and Ki-67 expression, are scarce. The aims of this study were to compare two methods of assessment of Ki-67, verify their prognostic impact, and define a threshold value based on survival. Thirty-one cases of histologically diagnosed canine splenic hemangiosarcoma, which were treated with splenectomy and had full staging and follow-up information, were collected. Three were stage I, 17 stage II, and 11 stage III. The mean mitotic count (MC) was 23.9 (standard deviation [SD]: 22.1) and the median was 15 (range, 1-93). Immunohistochemistry for Ki-67 was performed, the Ki-67 labeling index (Ki-67LI) was assessed as a percentage of positive neoplastic nuclei per ≥500 cell, and the Ki-67 count (KI-67C) was defined as the average number of positive nuclei using a 1 cm2 optical grid performed in 5, 40× fields. The mean Ki-67LI and Ki-67C were 56.4% (SD: 38.7) and 27.2 (SD: 12.9) and medians were 51% (range, 8.2-55.2) and 26 (range, 5.5-148), respectively. Using a cut-off of 56% and 9, respectively, Kaplan-Meier survival curves showed an association of overall survival with Ki-67LI and MC. In addition to clinical stage, Ki-67LI maintained its prognostic value on multivariate analysis, supporting the role of Ki-67LI as an independent prognostic parameter. Based on these results, we propose a diagnostically applicable cut-off value of 56% for Ki-67LI as a prognostic parameter for canine splenic hemangiosarcoma.
Asunto(s)
Enfermedades de los Perros , Hemangiosarcoma , Antígeno Ki-67 , Neoplasias del Bazo , Hemangiosarcoma/veterinaria , Hemangiosarcoma/patología , Hemangiosarcoma/metabolismo , Hemangiosarcoma/diagnóstico , Animales , Antígeno Ki-67/metabolismo , Enfermedades de los Perros/patología , Enfermedades de los Perros/metabolismo , Enfermedades de los Perros/diagnóstico , Perros , Pronóstico , Neoplasias del Bazo/veterinaria , Neoplasias del Bazo/patología , Neoplasias del Bazo/diagnóstico , Neoplasias del Bazo/metabolismo , Masculino , Femenino , Inmunohistoquímica/veterinaria , Esplenectomía/veterinaria , Índice Mitótico/veterinaria , Estadificación de Neoplasias/veterinaria , Biomarcadores de Tumor/metabolismoRESUMEN
Gastrointestinal lymphomas are uncommon in dogs and little is known about their distinct subtypes or proliferation rate. The aim of this study was to stratify 33 canine gastrointestinal lymphoma samples according to the latest World Health Organization classification and to determine the Ki67 proliferation index by manual counting, digital image analysis and visual estimation. The Ki67 index was then correlated with subtype, immunophenotype, mitotic index, grade and tumour location. The mitotic index correlated positively with the Ki67 index. A significantly higher number of Ki67-positive cells was found in enteropathy-associated T-cell lymphoma type I and in diffuse large B-cell lymphoma compared with enteropathy-associated T-cell lymphoma type II. There was also a significant difference in Ki67 immunolabelled cells between grade 1 and grade 2 lymphomas. Moderate agreement was found between the Ki67 index as obtained by manual counting and visual estimation, but there was strong agreement between manual counting and digital image analysis. The user-friendly digital imaging system used in this study could have potential for future determination of the Ki67 index in lymphoid neoplasms.
Asunto(s)
Enfermedades de los Perros , Neoplasias Gastrointestinales , Linfoma de Células B Grandes Difuso , Animales , Proliferación Celular , Perros , Neoplasias Gastrointestinales/veterinaria , Antígeno Ki-67 , Linfoma de Células B Grandes Difuso/veterinaria , Índice Mitótico/veterinariaRESUMEN
OBJECTIVES: The objective of this retrospective study was to evaluate the outcome of dogs when grade II mast cell tumour (MCT) with low mitotic index (MI) and high Ki67 were treated with adjuvant lomustine. ANIMALS: Client owned dogs with spontaneously occurring disease treated with adjuvant chemotherapy for grade II mast cell tumour with low MI (≤5/10HPF) and high Ki67 (>1.8%) with no evidence of metastatic disease at presentation. PROCEDURES: Lomustine was administered every 3 weeks with three or four planned cycles. Response to treatment was assessed by regular re-staging ultrasound with or without cytopathological examination of liver and spleen or through medical records from the referring veterinarian. Disease-free interval (DFI) and median survival time (MST) were calculated using Kaplan-Meier method. RESULTS: Twenty-one dogs were included. All dogs underwent surgical excision and two dogs received adjuvant radiotherapy. None of the patients developed local recurrence. Three dogs (14.3%) developed metastatic disease. The DFI of these dogs was 141, 186 and 223 days. Median follow-up period of the whole study population was 1112 days (358-2619). MST for patients with metastatic disease was 417 days. MST of the whole group was not reached. One-year and 2-year survivals were 95.2% and 90.5%, respectively. CONCLUSIONS AND CLINICAL RELEVANCE: This study population had low rates of tumour recurrence and improved survival compared to previously published data of similar population of dogs with low MI/high Ki67 MCT without adjuvant chemotherapy.
Asunto(s)
Enfermedades de los Perros , Lomustina , Animales , Enfermedades de los Perros/tratamiento farmacológico , Enfermedades de los Perros/cirugía , Perros , Antígeno Ki-67 , Lomustina/uso terapéutico , Mastocitos , Índice Mitótico/veterinaria , Estudios RetrospectivosRESUMEN
Counting mitotic figures (MF) in hematoxylin and eosin-stained histologic sections is an integral part of the diagnostic pathologist's tumor evaluation. The mitotic count (MC) is used alone or as part of a grading scheme for assessment of prognosis and clinical decisions. Determining MCs is subjective, somewhat laborious, and has interobserver variation. Proposals for standardizing this parameter in the veterinary field are limited to terminology (use of the term MC) and area (MC is counted in an area measuring 2.37 mm2). Digital imaging techniques are now commonplace and widely used among veterinary pathologists, and field of view area can be easily calculated with digital imaging software. In addition to standardizing the methods of counting MF, the morphologic characteristics of MF and distinguishing atypical mitotic figures (AMF) versus mitotic-like figures (MLF) need to be defined. This article provides morphologic criteria for MF identification and for distinguishing normal phases of MF from AMF and MLF. Pertinent features of digital microscopy and application of computational pathology (CPATH) methods are discussed. Correct identification of MF will improve MC consistency, reproducibility, and accuracy obtained from manual (glass slide or whole-slide imaging) and CPATH approaches.
Asunto(s)
Programas Informáticos , Animales , Eosina Amarillenta-(YS) , Hematoxilina , Índice Mitótico/veterinaria , Reproducibilidad de los ResultadosRESUMEN
Squamous cell carcinoma (SCC) is a frequent malignant neoplasm of the skin that usually arises from areas of solar dermatosis. It is characterized by local invasiveness and regional lymph node metastasis, mainly in poorly differentiated tumours. Galectin-3 (Gal-3) is a lectin that is expressed in the nucleus or cytoplasm and has been identified as a prognostic tool for human neoplasms. The purpose of this study was to characterize Gal-3 expression in canine cutaneous SCCs and to investigate its relationship with tumour differentiation and cell proliferation indices. Immunohistochemical analysis of 50 SCCs for Gal-3 revealed no correlation between the localization or intensity of immunolabelling, or number of immunopositive cells, with histological grade of tumour or proliferative activity. The results suggest that Gal-3 expression is not a reliable prognostic marker for cutaneous SCC in dogs.
Asunto(s)
Carcinoma de Células Escamosas/veterinaria , Enfermedades de los Perros , Galectina 3/metabolismo , Animales , Biomarcadores de Tumor , Carcinoma de Células Escamosas/patología , Proliferación Celular , Perros , Inmunohistoquímica/veterinaria , Índice Mitótico/veterinaria , Clasificación del Tumor/veterinaria , Pronóstico , Neoplasias Cutáneas/patología , Neoplasias Cutáneas/veterinariaRESUMEN
OBJECTIVES: To describe the clinicopathological and genetic characteristics of mast cell tumours in dogs less than 12 months old. MATERIALS AND METHODS: Retrospective review of dogs aged less than 12 months when diagnosed with mast cell tumours at three referral hospitals in the UK. RESULTS: Sixteen pure-bred dogs were included, of which 11 were female. The median age at first presentation and diagnosis were 7.6 and 9 months, respectively. In 13 dogs the mast cell tumours were cutaneous and in three they were subcutaneous. Four cutaneous mast cell tumours were described as high-grade (Patnaik or Kiupel) and nine were Patnaik grade II; three had mitotic index of >5 in 10 high-power fields. Of the three subcutaneous tumours, two had an infiltrative growth pattern and one had mitotic index of 10 per 10 high-power fields. Of 10 tested dogs, seven had c-kit mutations in exon 11 and Ki-67 score was above the cut-off value in nine. Four of 12 cases showed evidence of metastasis in the regional lymph nodes. After varying treatment protocols, all patients were alive and disease free at a median of 1115 days after diagnosis. CLINICAL SIGNIFICANCE: The prognosis of mast cell tumours in dogs less than a year old appears better than the adult counterparts, even without extensive treatment.
Asunto(s)
Enfermedades de los Perros , Neoplasias Cutáneas/veterinaria , Animales , Perros , Femenino , Mastocitos , Índice Mitótico/veterinaria , Pronóstico , Estudios RetrospectivosRESUMEN
Mitotic count (MC) is an important element for grading canine cutaneous mast cell tumors (ccMCTs) and is determined in 10 consecutive high-power fields with the highest mitotic activity. However, there is variability in area selection between pathologists. In this study, the MC distribution and the effect of area selection on the MC were analyzed in ccMCTs. Two pathologists independently annotated all mitotic figures in whole-slide images of 28 ccMCTs (ground truth). Automated image analysis was used to examine the ground truth distribution of the MC throughout the tumor section area, which was compared with the manual MCs of 11 pathologists. Computerized analysis demonstrated high variability of the MC within different tumor areas. There were 6 MCTs with consistently low MCs (MC<7 in all tumor areas), 13 cases with mostly high MCs (MC ≥7 in ≥75% of 10 high-power field areas), and 9 borderline cases with variable MCs around 7, which is a cutoff value for ccMCT grading. There was inconsistency among pathologists in identifying the areas with the highest density of mitotic figures throughout the 3 ccMCT groups; only 51.9% of the counts were consistent with the highest 25% of the ground truth MC distribution. Regardless, there was substantial agreement between pathologists in detecting tumors with MC ≥7. Falsely low MCs below 7 mainly occurred in 4 of 9 borderline cases that had very few ground truth areas with MC ≥7. The findings of this study highlight the need to further standardize how to select the region of the tumor in which to determine the MC.
Asunto(s)
Enfermedades de los Perros/patología , Técnicas Histológicas/veterinaria , Neoplasias Cutáneas/veterinaria , Animales , Recuento de Células/veterinaria , Perros , Procesamiento de Imagen Asistido por Computador , Mastocitos/patología , Índice Mitótico/veterinaria , Clasificación del Tumor/veterinaria , Variaciones Dependientes del Observador , Patólogos , Neoplasias Cutáneas/patología , Programas InformáticosAsunto(s)
Biopsia con Aguja Fina/veterinaria , Carcinoma Hepatocelular/veterinaria , Enfermedades de los Perros/patología , Neoplasias Hepáticas/veterinaria , Animales , Carcinoma Hepatocelular/patología , Enfermedades de los Perros/diagnóstico , Perros , Femenino , Hígado/patología , Neoplasias Hepáticas/patología , Índice Mitótico/veterinaria , Variaciones Dependientes del ObservadorRESUMEN
BACKGROUND: Gastrointestinal stromal tumors (GISTs) are uncommon intestinal neoplasms in the dog. Literature regarding adjunctive therapy for GISTs in dogs is sparse. High-risk GISTs in humans respond to tyrosine kinase inhibition in the adjuvant setting. OBJECTIVES: To review cases of toceranib phosphate use in dogs with GISTs and provide initial assessment of possible biological activity. A secondary aim was to evaluate patient and tumor characteristics for possible prognostic value. ANIMALS: Twenty-seven dogs with confirmed GISTs based on histopathology and immunohistochemistry treated with toceranib. METHODS: Retrospective study in which cases of toceranib use in dogs with GIST were solicited using the American College of Veterinary Internal Medicine Oncology and Small Animal Internal Medicine listservs. RESULTS: Five of 7 dogs with gross disease experienced clinical benefit (71%; 3 complete responses, 1 partial response, 1 stable disease). These included 2 dogs with durable responses after toceranib discontinuation. Median progression-free interval (PFI) in dogs with gross disease was 110 weeks (range, 36-155 weeks). Median PFI in dogs with microscopic disease was 67 weeks (range, 9-257 weeks). Metastasis at diagnosis (P = 0.04) and high mitotic index (P < 0.001) were associated with shorter PFI in toceranib-treated dogs. CONCLUSIONS AND CLINICAL IMPORTANCE: Biological activity of toceranib is evident in dogs with gross disease. Metastasis of GIST at diagnosis, as well as high tumor mitotic index, was associated with shorter PFI in toceranib-treated dogs. Larger studies are needed to define postsurgical risk and refine the use of toceranib in dogs with gross and microscopic GIST.
Asunto(s)
Antineoplásicos/uso terapéutico , Enfermedades de los Perros/tratamiento farmacológico , Neoplasias Gastrointestinales/veterinaria , Tumores del Estroma Gastrointestinal/veterinaria , Indoles/uso terapéutico , Pirroles/uso terapéutico , Animales , Enfermedades de los Perros/diagnóstico , Enfermedades de los Perros/patología , Perros , Femenino , Neoplasias Gastrointestinales/diagnóstico , Neoplasias Gastrointestinales/tratamiento farmacológico , Neoplasias Gastrointestinales/patología , Tumores del Estroma Gastrointestinal/diagnóstico , Tumores del Estroma Gastrointestinal/tratamiento farmacológico , Tumores del Estroma Gastrointestinal/patología , Masculino , Índice Mitótico/veterinaria , Pronóstico , Supervivencia sin Progresión , Estudios RetrospectivosRESUMEN
A previous study found that minichromosome maintenance protein 7 (MCM7) score was associated with prognosis in dogs with cutaneous mast cell tumours (MCTs) independent of histological grade. The primary aim of this study was to validate this score in a different cohort of dogs focusing exclusively on patients with Patnaik intermediate grade MCTs treated with surgery alone and followed for a minimum of 1 year. A secondary aim was to evaluate the prognostic performance of MCM7 in relation to Kiupel histological grade, mitotic index (MI) and Ki67 index in the same cohort of dogs. Ninety dogs were identified, 82 were low Kiupel grade and 8 were high Kiupel grade. Seventy-two dogs were alive after a median follow-up of 1136 days and 18 dogs died of MCT-related causes after a median of 116 days. A MI threshold of 5 was associated with a sensitivity of 0.39 and a specificity of 0.99 in predicting MCT-related death; for Ki67 a threshold of 0.018 was associated with a sensitivity of 0.78 and a specificity of 0.83; and for MCM7 a threshold of 0.18 gave a sensitivity of 0.83 and a specificity of 0.86. Combining MI, Ki67 and MCM7 showed an improved accuracy of predicting death compared with each individual variable. Therefore, performing Ki67 and MCM7 in dogs with GII MCT, low Kiupel grade and low MI might be a consideration.
Asunto(s)
Enfermedades de los Perros/diagnóstico , Antígeno Ki-67/metabolismo , Mastocitosis Cutánea/veterinaria , Componente 7 del Complejo de Mantenimiento de Minicromosoma/metabolismo , Índice Mitótico/veterinaria , Animales , Biomarcadores de Tumor/metabolismo , Enfermedades de los Perros/mortalidad , Enfermedades de los Perros/patología , Perros , Femenino , Masculino , Mastocitosis Cutánea/diagnóstico , Mastocitosis Cutánea/mortalidad , Mastocitosis Cutánea/patología , Pronóstico , Sensibilidad y Especificidad , Piel/patologíaRESUMEN
Metastatic rates and survival times of canine anal sac gland adenocarcinomas (ASGACs) vary among studies, making prognostication difficult. Little is known about the prognostic significance of histopathology of ASGACs. This retrospective study investigated associations between histological features, clinical presentation and outcome for 39 ASGACs. Most tumours were incompletely excised (62%) and had moderate to marked peripheral infiltration (74%). The predominant growth pattern was solid, tubules/rosettes/pseudorosettes and papillary in 49%, 46% and 5% of the cases, respectively. Nuclear pleomorphism was either moderate (77%) or mild (23%). Necrosis and lymphovascular invasion were present in 54% and 10% of the cases, respectively. All histological features except mitotic count and necrosis were associated with nodal metastasis at presentation. A statistically significant poorer outcome was identified for tumours with a solid growth pattern, moderate or marked peripheral infiltration, necrosis and lymphovascular invasion. These results need further validation in a larger cohort of dogs.
Asunto(s)
Adenocarcinoma/veterinaria , Neoplasias de las Glándulas Anales/patología , Sacos Anales/patología , Enfermedades de los Perros/patología , Adenocarcinoma/diagnóstico , Adenocarcinoma/patología , Adenocarcinoma/cirugía , Neoplasias de las Glándulas Anales/diagnóstico , Neoplasias de las Glándulas Anales/mortalidad , Neoplasias de las Glándulas Anales/cirugía , Animales , Supervivencia sin Enfermedad , Enfermedades de los Perros/diagnóstico , Enfermedades de los Perros/mortalidad , Enfermedades de los Perros/cirugía , Perros , Femenino , Masculino , Márgenes de Escisión , Índice Mitótico/veterinaria , Pronóstico , Estudios Retrospectivos , Análisis de SupervivenciaRESUMEN
Canine histiocytic sarcoma (HS) is an aggressive and highly metastatic tumor. Previously, the kinase inhibitor dasatinib was shown to have potent growth inhibitory activity against HS cells in vitro, possibly via targeting the EPHA2 receptor. Here, the in vivo effect of dasatinib in HS cells was investigated using a xenograft mouse model. Moreover, the expression status of EPHA2 was examined in six HS cell lines, ranging from insensitive to highly sensitive to dasatinib. In the HS xenograft mouse model, dasatinib significantly suppressed tumor growth, as illustrated by a decrease in mitotic and Ki67 indices and an increase in apoptotic index in tumor tissues. On Western blot analysis, EPHA2 was only weakly detected in all HS cell lines, regardless of sensitivity to dasatinib. Dasatinib likely results in the inhibition of xenograft tumor growth via a mechanism other than targeting EPHA2. The findings of this study suggest that dasatinib is a targeted therapy drug worthy of further exploration for the treatment of canine HS.
Asunto(s)
Antineoplásicos/farmacología , Dasatinib/farmacología , Enfermedades de los Perros/tratamiento farmacológico , Sarcoma Histiocítico/veterinaria , Receptor EphA2/metabolismo , Animales , Apoptosis/efectos de los fármacos , Western Blotting/veterinaria , Línea Celular Tumoral , Modelos Animales de Enfermedad , Perros , Femenino , Sarcoma Histiocítico/tratamiento farmacológico , Técnicas In Vitro , Ratones , Ratones Endogámicos BALB C , Índice Mitótico/veterinaria , Trasplante de Neoplasias/veterinariaRESUMEN
The pioneering study of Eyal-Giladi and Kochav (EG&K; Eyal-Giladi and Kochav, 1976) on the early developmental stages-from fertilization, through oviposition, to the gastrulation process-set the standard for characterizing chicken embryos, and has been used in numerous studies over the years. During uterine development, the chicken embryo undergoes dramatic changes, extremely rapid cell cycles, massive cell death, and axial determination processes. However, once the egg is laid, the temperature drops and the embryo enters into a diapause-like state. This phenomenon is utilized to store fertile eggs prior to incubation. The ability to resume development to hatching, following storage, relies on several factors, including the number of living cells and the embryonic developmental stage. These factors are highly influenced by the storage conditions-mainly duration and temperature. Thus, to study the effects of storage conditions on embryonic viability, a comprehensive characterization of the starting point-shortly after oviposition-is needed. In this study, we characterized freshly laid broiler eggs from Ross 308 flocks for embryonic developmental stage, total cell count, and cell viability. Using the novel high-resolution episcopic microscopy (HREM) system, we show, for the first time, high-resolution 3D morphological models of blastoderms which allow for highly accurate embryonic staging. Staging was also done under a dissecting microscope thus allowing for a direct side-by-side comparison of the two methods. Analysis of freshly laid blastomeres showed that the total nucleus count increases with developmental stage from â¼60,000 at stage X EG&K to â¼130,000 at stage XIII EG&K, whereas the proportion of mitotic index and dying cells at oviposition are â¼2% and â¼5%, respectively. Moreover, staging embryos from young and old flocks revealed that the blastoderms of the old flocks are more developed. Specifically, the predominant embryonic stages were XI and XII EG&K in young and old flocks, respectively. Collectively, we characterized parameters that can serve to analyze the maladaptive effects of prolonged storage under various conditions on embryo survival.
Asunto(s)
Crianza de Animales Domésticos/métodos , Blastodermo/fisiología , Embrión de Pollo/fisiología , Pollos/fisiología , Óvulo/crecimiento & desarrollo , Animales , Blastodermo/citología , Blastodermo/embriología , Recuento de Células/métodos , Supervivencia Celular , Embrión de Pollo/embriología , Embrión de Pollo/crecimiento & desarrollo , Embriología/métodos , Índice Mitótico/veterinariaRESUMEN
BACKGROUND: Ki67 index, tumor associated macrophages (TAMs) and mast cells (MCs) are associated with malignancies in animal and human neoplasms including colorectal carcinomas (CRC). This has not been assessed in canine CRC. Given similar genetic abnormalities between human and canine CRC, we assessed Ki-67 and mitotic indices, TAMs and MC count (MCC) in canine CRC (n = 17). TAMs and MCC were compared with those in adenomas (n = 13) and control (n = 9). RESULTS: Ki-67 index in CRC (17.13 ± 11.50) was strongly correlated (r = 0.98, p < 0.05) with mitotic index (3.52 ± 1.80). MCC was higher (p < 0.05) in CRC (6.30 ± 3.98) than in adenomas (0.78 ± 0.77) and control (0.35 ± 0.33). The results suggest that Ki-67 index and MCC are associated with malignancy in canine CRC. Higher average TAMs were counted in adenomas (21.30 ± 20.70) and in CRC (11.00 ± 9.82) than in the control (7.69 ± 7.26), although the differences were not significant (p > 0.05). CONCLUSION: Ki-67 index, TAMs and MCC in canine CRC were recorded for the first time in this study. Ki-67 index and MCC are associated with malignancy in canine CRC. Quantitative assessment of MCs and Ki-67 coupled with mitotic index and other clinical parameters may help in evaluating malignancy in canine CRC. TAMs likely play a role in the development of canine colorectal tumors. Further studies to determine the clinical significance of these parameters for prognostic, chemo-preventive and chemotherapeutic purposes in canine colorectal tumors are recommended.
Asunto(s)
Neoplasias Colorrectales/veterinaria , Enfermedades de los Perros/inmunología , Antígeno Ki-67/metabolismo , Macrófagos/inmunología , Mastocitos/inmunología , Adenoma/inmunología , Adenoma/veterinaria , Animales , Carcinoma/inmunología , Carcinoma/veterinaria , Neoplasias Colorrectales/inmunología , Perros , Macrófagos/metabolismo , Mastocitos/metabolismo , Índice Mitótico/veterinariaRESUMEN
Feline injection-site sarcoma (FISS) is commonly treated with surgery and radiation therapy. Despite aggressive therapy, FISS has a high recurrence rate. The true benefit of adjuvant chemotherapy is not known. DNA damage response mechanisms help protect against genomic instability but can also promote chemoresistance. In order to determine whether DNA damage is a feature of FISS, we evaluated tumour tissues with γH2AX immunohistochemistry. H2AX is phosphorylated to form γH2AX following DNA double strand breaks. Seventeen FISS specimens were evaluated prospectively. DNA damage ranged from 2.18 to33.7%, with a median of 16.2%. Significant differences were noted between cats (P < 0.0001). Mitotic index ranged from 0 to 57 with a median of 13 and did not correlate with γH2AX positivity (P = 0.2). Further studies are needed to determine if γH2AX expression may predict chemosensitivity and have independent value as a prognostic factor.
Asunto(s)
Enfermedades de los Gatos/etiología , Daño del ADN , Sarcoma/veterinaria , Neoplasias de los Tejidos Blandos/veterinaria , Animales , Enfermedades de los Gatos/metabolismo , Enfermedades de los Gatos/patología , Gatos , Femenino , Histonas/metabolismo , Inyecciones/efectos adversos , Inyecciones/veterinaria , Masculino , Índice Mitótico/veterinaria , Sarcoma/etiología , Sarcoma/metabolismo , Sarcoma/patología , Neoplasias de los Tejidos Blandos/etiología , Neoplasias de los Tejidos Blandos/metabolismo , Neoplasias de los Tejidos Blandos/patologíaRESUMEN
Limited veterinary literature is available regarding prognostic markers for canine renal cell carcinoma (CRCC). We retrospectively evaluated COX-2 expression, histological and clinical features associated with prognosis of CRCC. Sixty-four cases post-nephrectomy were included, 54 had histopathological assessment and 30 had COX-2 immunostaining performed. Eight dogs (13%) had metastatic disease at initial diagnosis. Twenty-seven dogs (42%) received adjuvant therapy after nephrectomy. On univariate analysis, COX-2 expression, mitotic index (MI), histologic type, vascular invasion, neoplastic invasiveness and metastasis at diagnosis were significantly associated with overall median survival time (MST). COX-2 score (COX-2 score > 3 MST 420 days versus 1176 days if COX-2 score <3; P = 0.011) and MI (MI > 30 MST 120 days versus 540 days for MI < 30; P = 0.003) were the only variables associated with CRCC outcome on multivariate analysis. The addition of MI and COX-2 immunostaining to standard histopathological evaluation would help predicting outcome in CRCC patients.
Asunto(s)
Carcinoma de Células Renales/veterinaria , Ciclooxigenasa 2/metabolismo , Enfermedades de los Perros/diagnóstico , Neoplasias Renales/veterinaria , Nefrectomía/veterinaria , Animales , Carcinoma de Células Renales/diagnóstico , Carcinoma de Células Renales/patología , Carcinoma de Células Renales/cirugía , Enfermedades de los Perros/mortalidad , Enfermedades de los Perros/patología , Enfermedades de los Perros/cirugía , Perros , Femenino , Neoplasias Renales/diagnóstico , Neoplasias Renales/patología , Neoplasias Renales/cirugía , Masculino , Índice Mitótico/veterinaria , Invasividad Neoplásica/patología , Pronóstico , Estudios Retrospectivos , Análisis de Supervivencia , Resultado del TratamientoRESUMEN
Choroid plexus tumors (CPTs) are reported with an increasing incidence in dogs, and they call for a reexamination of histologic features and criteria of classification corresponding to their biological behavior. In this study, the human World Health Organization classification was applied to 16 canine CPTs, and the expression of molecules involved in neoplastic cell adhesion (E-cadherin, N-cadherin), invasion (doublecortin), and proliferation (Ki-67) was investigated. Mitotic index was found to be the main criterion for grading CPTs. Cell density and multilayering of papillae were also statistically associated with histologic grade. Intraventricular spread and parenchymal invasion was observed for tumors showing histologic benign features. E-cadherin was expressed in all CPT grades, independent of tumor invasion. N-cadherin immunolabeling was more expressed in grade I than high-grade CPTs, whereas doublecortin expression was not detected in CPTs. An increasing proliferative activity was observed in relation with histologic grade.
Asunto(s)
Cadherinas/metabolismo , Neoplasias del Plexo Coroideo/veterinaria , Enfermedades de los Perros/clasificación , Animales , Neoplasias del Plexo Coroideo/clasificación , Neoplasias del Plexo Coroideo/metabolismo , Neoplasias del Plexo Coroideo/patología , Enfermedades de los Perros/metabolismo , Enfermedades de los Perros/patología , Perros , Femenino , Inmunohistoquímica/veterinaria , Masculino , Índice Mitótico/veterinaria , Clasificación del Tumor/veterinariaRESUMEN
OBJECTIVES: To assess correlation between Ki67 index and mitotic index and determine which more accurately predicts survival in canine mast cell tumours. METHODS: Retrospective analysis of cases from three UK referral hospitals. Correlation between Ki67 index and mitotic index was assessed and survival analysis performed. RESULTS: A total of 162 dogs were included: 57 dogs died with 37 due to mast cell tumour. Correlation between Ki67 index and mitotic index was moderate, while the agreement was poor. A high Ki67 index was considered sensitive (86 · 5%) at predicting mast cell tumour-related death, but poorly specific (57 · 9%). Mitotic index(>5) was poorly sensitive (32 · 4%), but highly specific (96%). A mitotic index of ê2 had a 75 · 7% sensitivity and an 80 · 0% specificity. Ki67 index showed a statistically significant survival difference within the mitotic index <2 (P = 0 · 009) group. Ki67 index did not predict survival rate in tumours with mitotic index of ê2. CLINICAL RELEVANCE: Correlation between Ki67 and mitotic index is moderate. High mitotic index accurately predicted death, but many dogs with low mitotic index also died. Low Ki67 accurately predicted survival, but high Ki67 should not be considered a poor prognostic indicator. A three-tier mitotic index assessment may more accurately predict death due to mast cell tumour.